 |
Case Report
A giant occipital malignant peripheral nerve sheath tumor in non-neurofibromatosis person: A rare case and review of literature
1 Professor, Department of Surgery, Nnamdi Azikiwe University, Awka, Nigeria
2 Lecturer, Department of Surgery, Nnamdi Azikiwe University, Awka, Nigeria
3 Senior Resident, Department of Surgery, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
4 Resident, Department of Surgery, Nnamdi Azikiwe University Teaching Hospital, Nnewi, Anambra State, Nigeria
Address correspondence to:
JKC Emejulu
Department of Surgery, Nnamdi Azikiwe University, Awka,
Nigeria
Message to Corresponding Author
Article ID: 101157Z01JE2020
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Emejulu JKC, Nkwerem SPU, Ekweogwu OC, Okpalike IV, Nwosu RC, Okwunze CL. A giant occipital malignant peripheral nerve sheath tumor in non-neurofibromatosis person: A rare case and review of literature. Int J Case Rep Images 2020;11:101157Z01JE2020.ABSTRACT
Introduction: Malignant peripheral nerve sheath tumor (MPNST) is an aggressive tumor which is often associated with neurofibromatosis type-1 (NF-1). This rare tumor is often associated with nerve roots and bundles in the extremities. Occipital MPNST is rare. Giant size occipital scalp MPNST is extremely rare in literature. The size of tumor often becomes difficult to treat. We present one of the most gigantic occipital MPNSTs (14 × 27 × 44 cm) published in the literature.
Case Report: A 27-year-old lady who presented with a huge occipital mass and a history suggestive of bilateral pathological fracture of the tibia. At presentation her occipital mass measured 14 × 27 × 44 cm. Cranial computed tomography (CT) showed evidence of calvarial erosion. She had subtotal tumor resection with histology suggestive of MPNST while immunohistochemistry was positive for S-100. She was referred to the oncology unit for chemoradiation.
Conclusion: Huge occipital MPNST presents management challenges because treatment is difficult. This giant MPNST has been added to the body of knowledge while the search for the ultimate solution continues.
Keywords: Giant, Malignant peripheral sheath tumor, Non-neurofibromatosis 1, Occipital
Introduction
The malignant peripheral nerve sheath tumor (MPNST) is a rare aggressive tumor of the connective tissues surrounding the nerves. This tumor, occasionally referred to as malignant schwannoma, malignant neurilemmoma, neurofibrosarcoma, and neurogenic sarcoma, constitutes 5–10% of all sarcomas in adults [1],[2]. It is found in 50% of neurofibromatosis type-1 (NF-1), an autosomal dominant disorder, while the others are sporadic in occurrence or radiation induced [1]. This rare tumor is often associated with nerve roots and bundles in extremities and pelvis. Malignant peripheral nerve sheath tumors are uncommon in the head [3]. An early presentation may make a wide local excision curative; other treatment modalities include chemotherapy and radiotherapy [4].
We present a case of a giant, grotesque occipital malignant nerve sheath tumor which was recently managed in our service (Figure 1) and also review the literature.
Case Report
A 27-year-old right handed woman with a posterior scalp swelling of six months duration, which was insidious in onset and progressively increasing in size, associated with intermittent dull pains. There was no associated irrational talk, seizure, altered level of consciousness, visual impairment, double vision, or hemi-body weakness. There was neither associated café-au-lait spots nor skin lesions. About five months following the onset of symptoms, she developed bilateral closed tibial fractures following a minor fall. There was no history of fever or preceding trauma before the onset of symptoms. She had no history suggestive of anorexia or weight loss. There was a history of herbal medication initially but, because of the progression of the mass, she sought orthodox treatment.
At presentation, she was fully conscious and alert, and was not in any obvious distress. She was slightly overweight, otherwise, her general clinical condition was unremarkable. There was a huge, tense, cystic soft tissue, left paramedian occipital mass, extending to the middle. The mass was 14 × 27 × 44 cm in dimension (Figure 1), and slightly tender. It did not transilluminate and there was no associated skin nodules or pigmented skin patches. She had normal bilateral visual acuity. There was bilateral lower extremity edema and deformities with splints and crepe bandage in situ. X-ray images showed a left upper-third tibial fracture and right lower-third femoral fracture.
Cranial computed tomography showed a left parietal extra-axial mass with an underlying calvarial defect (barely short of the sagittal suture), with a mixed density extracranial component (hypodense-isodense) that was heterogeneously contrast enhancing (Figure 2). There was an unremarkable metastatic work-up.
A diagnosis of left occipital scalp mass with intracranial extension was made. The plastic surgery was also invited to review. She was subsequently worked up and had craniectomy and subtotal gross tumor excision through a midline scalp incision (Figure 3). The tumor capsule was peeled off the overlying redundant skin. The adjoining periosteum was completely excised, edges of bony defect nibbled till healthy bone was encountered (see arrow in Figure 4) and residual tumor which was adherent to the dura coagulated and the infiltrated dura excised. Dural defect was repaired with a harvested occipital fascia. The redundant and denuded skin was trimmed to size (Figure 5). Tumor specimen and postoperative cranial computed tomography are shown in Figure 6 and Figure 7, respectively. Histology report was diagnostic of a MPNST, while immunohistochemistry was positive for S-100, but negative for epithelial membrane antigen (EMA) and desmin. She was, subsequently, referred to the radio-oncology. Cranioplasty was planned as a second-stage procedure. She had radiotherapy and two courses of ifosfamide and epirubicin before she was lost to follow up.
Discussion
Malignant peripheral nerve sheath tumor is a rare tumor constituting about 2–6% of all sarcomas [5],[6]. It has no gender predilection, and tends to affect adults aged between 20 and 50 years [7]. The tumor can affect any part of the body especially the trunk and extremities, and the sciatic nerve, brachial plexus, and sacral plexus are the most common locations [8]. Occipital scalp MPNST is extremely rare (Table 1) [1],[9],[10],[11],[12],[13],[14],[15],[16],[17],[18],[19],[20],[21],[22],[23],[24],[25].
The etiology of MPNST has remained largely unknown, however, there are some genetic mutations so far identified with MPNST, and they include NF-1 and TP53. Both therapeutic and environmental radiation exposures have also been associated with this rare tumor [26],[27]. The NF-1 which is located on chromosome 17q11 codes for neurofibromin is known to take part, ultimately, in the inhibition of the p21ras signaling pathway. The loss of this regulatory pathway has been observed in transformation of the NF-1 to MPNST. Other genetic mutations observed include the T53 point mutation or deletion, deletion of the CDKN2A, RB1 tumor suppression gene [28],[29]. Yuan et al. have also noted excessive expression of some biomarkers, particularly S-100 and Ki67 in MPNSTs patients [30]. The biomarkers help in easy distinction between benign nerve sheath tumor and the malignant variety.
The MPNSTs are highly invasive and readily metastatic, the index case presented with bilateral pathological femoral fractures and obvious calvarial erosion in 6-month history, making complete cure a difficult task.
Complete surgical resection with margin ≥2 cm is important for complete resection. Radical resection with adjuvant radiotherapy is the mainstay of treatment [31]. Generally, in MPNSTs that are high grade, large (>5 cm), surgically inaccessible, or metastatic, complete resection is often difficult, hence subtotal resection may be what is achievable [29],[31].
Adjuvant radiotherapy is recommended for patient with large high grade tumor (>5 cm) or with microscopically (R1) or macroscopically (R2) positive resected tumor margins as a postoperative measure to reduce local recurrence and control pains [29]. Grotesque tumor size (14 × 27 × 44 cm) with calvarial erosion and dura infiltration, as well as distant metastasis, precludes cure. Late presentation to health care services may account for this tumor size which is one of the largest scalp MPNST in non-neurofibromatosis case published.
Chemotherapy and immunotherapy may also be useful therapeutic strategies [14],[25]. The use of chemotherapy in MPNST has not be very rewarding [1].
The index case had subtotal gross total tumor resection followed by chemoradiation.
Local recurrence rate and metastasis are at 40–65% and 40–68%, respectively [32]. In NF-1 patients, MPNST is the most common cause of mortality.
Conclusion
Management of a giant occipital MPNST remains a daunting task. Late presentation of patient with tumor makes treatment a difficult task. We believe that this case report will also add to the body of knowledge and data available for MPNST while the search for the ultimate cure for huge occipital MPNST continues.
REFERENCES
1.
Wang J, Ou SW, Guo ZZ, Wang YJ, Xing DG. Microsurgical management of giant malignant peripheral nerve sheath tumor of the scalp: Two case reports and a literature review. World J Surg Oncol 201310;11:269. [CrossRef]
[Pubmed]
2.
Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. Oncologist 2014;19(2):193–201. [CrossRef]
[Pubmed]
3.
Pourtsidis A, Doganis D, Baka M, et al. Malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1. Case Rep Oncol Med 2014;2014:843749. [CrossRef]
[Pubmed]
4.
Owosho AA, Estilo CL, Huryn JM, Chi P, Antonescu CR. A clinicopathologic study of head and neck malignant peripheral nerve sheath tumors. Head Neck Pathol 2018;12(2):151–9. [CrossRef]
[Pubmed]
5.
Scaife CL, Pisters PW. Combined-modality treatment of localized soft tissue sarcomas of the extremities. Surg Oncol Clin N Am 2003;12(2):355–68. [CrossRef]
[Pubmed]
6.
Ng VY, Scharschmidt TJ, Mayerson JL, Fisher JL. Incidence and survival in sarcoma in the United States: A focus on musculoskeletal lesions. Anticancer Res 2013;33(6):2597–604.
[Pubmed]
7.
Doyle LA. Sarcoma classification: An update based on the 2013 World Health Organization Classification of Tumors of Soft Tissue and Bone. Cancer 2014;120(12):1763–74. [CrossRef]
[Pubmed]
8.
Kchouk M, Rabet AM, Ghedas K, et al. Extensive malignant schwannoma of the sciatic nerve. Contribution of imaging techniques. [Article in French]. J Radiol 1993;74(12):641–4.
[Pubmed]
9.
George E, Swanson PE, Wick MR. Malignant peripheral nerve sheath tumors of the skin. Am J Dermatopathol 1989;11(3):213–21. [CrossRef]
[Pubmed]
10.
Dabski C, Reiman HM Jr, Muller SA. Neurofibrosarcoma of skin and subcutaneous tissues. Mayo Clin Proc 1990;65(2):164–72. [CrossRef]
[Pubmed]
11.
Kikuchi A, Akiyama M, Han-Yaku H, Shimizu H, Naka W, Nishikawa T. Solitary cutaneous malignant schwannoma. Immunohistochemical and ultrastructural studies. Am J Dermatopathol 1993;15(1):15–9. [CrossRef]
[Pubmed]
12.
Demir Y, Tokyol C. Superficial malignant schwannoma of the scalp. Dermatol Surg 2003;29(8):879–81. [CrossRef]
[Pubmed]
13.
Garg A, Gupta V, Gaikwad SB, et al. Scalp malignant peripheral nerve sheath tumor (MPNST) with bony involvement and new bone formation: Case report. Clin Neurol Neurosurg 2004;106(4):340–4. [CrossRef]
[Pubmed]
14.
Williams SB, Szlyk GR, Manyak MJ. Malignant peripheral nerve sheath tumor of the kidney. Int J Urol 2006;13(1):74–5. [CrossRef]
[Pubmed]
15.
Fukushima S, Kageshita T, Wakasugi S, et al. Giant malignant peripheral nerve sheath tumor of the scalp. J Dermatol 2006;33(12):865–8. [CrossRef]
[Pubmed]
16.
Kumar P, Jaiswal S, Agrawal T, Verma A, Datta NR. Malignant peripheral nerve sheath tumor of the occipital region: Case report. Neurosurgery 2007;61(6):E1334–5. [CrossRef]
[Pubmed]
17.
Ge P, Fu S, Lu L, Zhong Y, Qi B, Luo Y. Diffuse scalp malignant peripheral nerve sheath tumor with intracranial extension in a patient with neurofibromatosis type 1. J Clin Neurosci 2010;17(11):1443–4. [CrossRef]
[Pubmed]
18.
Hasturk AE, Basmaci M, Bayram C, Bozdogan N. Surgical management of recurrent malignant schwannoma of the scalp. J Craniofac Surg 2011;22(3):1120–2. [CrossRef]
[Pubmed]
19.
Shintaku M, Wada K, Wakasa T, Ueda M. Malignant peripheral nerve sheath tumor with fibroblastic differentiation in a patient with neurofibromatosis type 1: Imprint cytological findings. Acta Cytol 2011;55(5):467–72. [CrossRef]
[Pubmed]
20.
Voth H, Nakai N, Wardelmann E, et al. Malignant peripheral nerve sheath tumor of the scalp: Case report and review of the literature. Dermatol Surg 2011;37(11):1684–8. [CrossRef]
[Pubmed]
21.
Jhawar SS, Mahore A, Goel N, Goel A. Malignant peripheral nerve sheath tumour of scalp with extradural extension: Case report. Turk Neurosurg 2012;22(2):254–6. [CrossRef]
[Pubmed]
22.
Bouhafa T, Elmazghi A, Baissel H, Fatmi HE, Amart A, Hassouni K. Malignant peripheral nerve sheath tumours of the scalp: Case report and review of literature. International Journal of Clinical Medicine 2014;5(15):916–20. [CrossRef]
23.
Firdaus M, Gill AS, Mukarramah DA, et al. Malignant peripheral nerve sheath tumor of the scalp: Two rare case reports. Surg Neurol Int 2018;9:102. [CrossRef]
[Pubmed]
24.
Gupta A, Kumar R, Ojha BK, Chandra A. Giant malignant peripheral nerve sheath tumor of scalp in non-neurofibromatosis person: A rare case report. Indian J Neurosurg 2018;7:54–7. [CrossRef]
25.
Liu X, Li W, Yuan H, Gu W, Chen D. Surgical treatment of rare giant malignant tumors of the scalp: A report of 3 cases with different tumor types. Oncol Lett 2016;12(5):3411–16. [CrossRef]
[Pubmed]
26.
Dunn GP, Spiliopoulos K, Plotkin SR, et al. Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg 2013;118(1):142–8. [CrossRef]
[Pubmed]
27.
Zou C, Smith KD, Liu J, et al. Clinical, pathological, and molecular variables predictive of malignant peripheral nerve sheath tumor outcome. Ann Surg 2009;249(6):1014–22. [CrossRef]
[Pubmed]
28.
Jouhilahti EM, Peltonen S, Heape AM, Juha Peltonen J. The pathoetiology of neurofibromatosis 1. Am J Pathol 2011;178(5):1932–9. [CrossRef]
[Pubmed]
29.
Wu LMN, Lu QR. Therapeutic targets for malignant peripheral nerve sheath tumors. Future Neurol 2019;14(1). [CrossRef]
30.
Yuan Z, Xu L, Zhao Z, et al. Clinicopathological features and prognosis of malignant peripheral nerve sheath tumor: A retrospective study of 159 cases from 1999 to 2016. Oncotarget 2017;8(62):104785–95. [CrossRef]
[Pubmed]
31.
Ziadi A, Saliba I. Malignant peripheral nerve sheath tumor of intracranial nerve: A case series review. Auris Nasus Larynx 2010;37(5):539–45. [CrossRef]
[Pubmed]
32.
Gousias K, Boström J, Kovacs A, Niehusmann P, Wagner I, Kristof R. Factors of influence upon overall survival in the treatment of intracranial MPNSTs. Review of the literature and report of a case. Radiat Oncol 2010;5:114. [CrossRef]
[Pubmed]
SUPPORTING INFORMATION
Author Contributions
JKC Emejulu - Conception of the work, Design of the work, Acquisition of data, Analysis of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
SPU Nkwerem - Conception of the work, Design of the work, Acquisition of data, Analysis of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
OC Ekweogwu - Conception of the work, Design of the work, Acquisition of data, Analysis of data, Drafting the work, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
IV Okpalike - Conception of the work, Design of the work, Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
RC Nwosu - Acquisition of data, Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
CL Okwunze - Acquisition of data, Analysis of data, Revising the work critically for important intellectual content, Final approval of the version to be published, Agree to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.
Guarantor of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2020 JKC Emejulu et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
